Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial

Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6rsDj4
via IFTTT